Clinical Trial

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-06-06; most recent amendment 2026-07-13.
Status change: Recruiting → Active, Not Recruiting 2026-07-13
Status change: Not Yet Recruiting → Recruiting 2021-08-10
Trial Details
NCT Number NCT04922658
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions Advanced Non-Small Cell Lung Cancer
Enrollment 76 participants
Start Date 2020-06-03
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15